International Tables for Crystallography (2006). Vol. F, ch. 1.3, pp. 10-25   | 1 | 2 |
doi: 10.1107/97809553602060000656

Chapter 1.3. Macromolecular crystallography and medicine

Contents

  • 1.3. Macromolecular crystallography and medicine  (pp. 10-25) | html | pdf | chapter contents |
    • 1.3.1. Introduction  (p. 10) | html | pdf |
    • 1.3.2. Crystallography and medicine  (pp. 10-11) | html | pdf |
    • 1.3.3. Crystallography and genetic diseases  (pp. 11-12) | html | pdf |
    • 1.3.4. Crystallography and development of novel pharmaceuticals  (pp. 12-24) | html | pdf |
      • 1.3.4.1. Infectious diseases  (pp. 13-15) | html | pdf |
        • 1.3.4.1.1. Viral diseases  (p. 13) | html | pdf |
        • 1.3.4.1.2. Bacterial diseases  (p. 13) | html | pdf |
        • 1.3.4.1.3. Protozoan infections  (pp. 13-15) | html | pdf |
        • 1.3.4.1.4. Fungi  (p. 15) | html | pdf |
        • 1.3.4.1.5. Helminths  (p. 15) | html | pdf |
      • 1.3.4.2. Resistance  (pp. 15-21) | html | pdf |
      • 1.3.4.3. Non-communicable diseases  (pp. 21-24) | html | pdf |
        • 1.3.4.3.1. Cancers  (p. 21) | html | pdf |
        • 1.3.4.3.2. Diabetes  (p. 21) | html | pdf |
        • 1.3.4.3.3. Blindness  (p. 21) | html | pdf |
        • 1.3.4.3.4. Cardiovascular disorders  (p. 21) | html | pdf |
        • 1.3.4.3.5. Neurological disorders  (p. 24) | html | pdf |
      • 1.3.4.4. Drug metabolism and crystallography  (p. 24) | html | pdf |
      • 1.3.4.5. Drug manufacturing and crystallography  (p. 24) | html | pdf |
    • 1.3.5. Vaccines, immunology and crystallography  (pp. 24-25) | html | pdf |
    • 1.3.6. Outlook and dreams  (p. 25) | html | pdf |
    • References | html | pdf |
    • Figures
      • Fig. 1.3.4.1. The structure-based drug design cycle  (p. 13) | html | pdf |
    • Tables
      • Table 1.3.3.1. Crystal structures and genetic diseases   (p. 11) | html | pdf |
      • Table 1.3.4.1. Important human pathogenic viruses and their proteins  (pp. 14-15) | html | pdf |
      • Table 1.3.4.2. Protein structures of important human pathogenic bacteria  (pp. 16-18) | html | pdf |
      • Table 1.3.4.3. Protein structures of important human pathogenic protozoa, fungi and helminths  (pp. 19-20) | html | pdf |
      • Table 1.3.4.4. Mechanisms of resistance  (p. 20) | html | pdf |
      • Table 1.3.4.5. Important human protein structures in drug design  (pp. 22-23) | html | pdf |